337 related articles for article (PubMed ID: 33234584)
1. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
2. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
3. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
[TBL] [Abstract][Full Text] [Related]
4. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
5. Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.
Oehrlein EM; Graff JS; Harris J; Perfetto EM
Patient; 2019 Aug; 12(4):375-381. PubMed ID: 30666526
[TBL] [Abstract][Full Text] [Related]
6. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
Polisena J; Jayaraman G
Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
[TBL] [Abstract][Full Text] [Related]
7. Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Takhar P; Geirnaert M; Gavura S; Beca J; Mercer RE; Denburg A; Muñoz C; Tadrous M; Parmar A; Dionne F; Boehm D; Chambers C; Craig E; Trudeau M; Cheung MC; Houlihan J; McDonald V; Pechlivanoglou P; Taylor M; Wasylenko E; Wranik WD; Chan KKW
Curr Oncol; 2024 Apr; 31(4):1876-1898. PubMed ID: 38668044
[TBL] [Abstract][Full Text] [Related]
8. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Parmar A; Dai WF; Dionne F; Geirnaert M; Denburg A; Ahuja T; Beca J; Bouchard S; Chambers C; Hunt MJ; Husereau D; Lungu E; McDonald V; Mercer RE; Mitera G; Muñoz C; Naipaul R; Peacock S; Potashnik T; Tadrous M; Takhar P; Taylor M; Trudeau M; Wasney D; Gavura S; Chan KKW
Curr Oncol; 2023 Mar; 30(4):3776-3786. PubMed ID: 37185399
[TBL] [Abstract][Full Text] [Related]
9. Paving the way for patient centricity in real-world evidence (RWE): Qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation.
Maruszczyk K; McMullan C; Aiyegbusi OL; Keeley T; Wilson R; Collis P; Bottomley C; Calvert MJ
Heliyon; 2023 Sep; 9(9):e20157. PubMed ID: 37809473
[TBL] [Abstract][Full Text] [Related]
10. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai WF; Arciero V; Craig E; Fraser B; Arias J; Boehm D; Bosnic N; Caetano P; Chambers C; Jones B; Lungu E; Mitera G; Potashnik T; Reiman A; Ritcher T; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group
Curr Oncol; 2021 Oct; 28(5):4174-4183. PubMed ID: 34677272
[TBL] [Abstract][Full Text] [Related]
11. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
12. Use of real-world evidence for oncology clinical decision making in emerging economies.
Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
[TBL] [Abstract][Full Text] [Related]
13. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
[TBL] [Abstract][Full Text] [Related]
14. Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned.
Evans WK; Takhar P; McDonald V; Elias M; Binder L; Michaud S; Tadrous M; Muñoz C; Chan KKW
Curr Oncol; 2022 Aug; 29(8):5616-5626. PubMed ID: 36005181
[TBL] [Abstract][Full Text] [Related]
15. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
[TBL] [Abstract][Full Text] [Related]
16. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
F1000Res; 2018; 7():111. PubMed ID: 30026923
[TBL] [Abstract][Full Text] [Related]
17. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
Timbie JW; Kim AY; Concannon TW
Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
[TBL] [Abstract][Full Text] [Related]
18. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
[TBL] [Abstract][Full Text] [Related]
19. Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Dai WF; Craig E; Fraser B; Chambers A; Mai H; Brown MB; Earle CC; Evans WK; Geirnaert M; Taylor M; Trudeau M; Sperber D; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
Curr Oncol; 2021 Nov; 28(6):4645-4654. PubMed ID: 34898572
[TBL] [Abstract][Full Text] [Related]
20. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM; Parmar A; Guo H; Schwartz D; Isaranuwatchai W; Beca J; Dai W; Arias J; Gavura S; Chan KKW
Cancer; 2020 Apr; 126(8):1717-1726. PubMed ID: 31913522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
